anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Despite the health benefits of physical activity, increasing regular physical activity levels among low-income, ethnic-minority mothers has remained a significant challenge. Yet, few studies have examined the feasibility of implementing interventions to address physical activity barriers often experienced by this population. The current mixed-methods feasibility study explored the impact that a three-month community-based (CBI) and a home-based intervention (HBI) had on improving physical activity and fitness levels, as well as psychosocial outcomes (self-efficacy and social support) among low-income, ethnic-minority mothers. Thirty mothers were randomized to either a three-month community-based intervention (CBI) or a home-based intervention (HBI) and completed pre- and post-intervention assessments of physical activity (self-report, accelerometer), fitness (cardiorespiratory, muscle endurance and strength, flexibility), self-efficacy, and social support. Post-intervention focus groups were also conducted. Through formative research, this pilot work will develop and empirically test a CBI and HBI among low-income mothers for use in local community centers. The results of the proposed work have substantial public health implications and are expected to advance the investigator's understanding of how low-income mothers effectively use these intervention modalities to adopt healthy behaviors and produce change that can positively impact their health, as well as that of their children. Further, the proposed research will yield two physical activity interventions that can be readily delivered in community settings, are scalable, and are relatively low cost. Finally, these results will help identify those subgroups of mothers that may do particularly well (or poorly) with these innovative approaches to physical activity adoption and maintenance. This has important implications for the tailoring of physical activity programs to individual needs and preferences.
Women with HPV self-collected tests receive usual care. Upon opting for the HPV self-collected test, women will be instructed to go to the health care center in 30 days to pick up the results.
Postoperative neurocognitive disorders (PoNCDs), such as postoperative delirium and cognitive dysfunction or decline can occur after surgery, especially in older patients. This significantly affects patient morbidity and surgical outcomes. Among various risk factors, recent studies have shown that preoperative frailty is associated with developing these conditions. Although the mechanisms underlying PoNCDs remain unclear, neuroinflammation appears to play an important role in their development. For the prevention and treatment of PoNCDs, medication modification, a balanced diet, and prehabilitation and rehabilitation programs have been suggested. The risk of developing PoNCDs is thought to be lower in ambulatory patients. However, owing to technological advancements, an increasing number of older and sicker patients are undergoing more complex surgeries and are often not closely monitored after discharge. Therefore, equal attention should be paid to all patient populations. This article presents an overview of PoNCDs and highlights issues of particular interest for ambulatory surgery.
FIELD: medicine, medicinal genetics. SUBSTANCE: method involves introduction of genetic material with enhancer of polynucleotide function (for example, bupivacaine) in cells of individual person. Molecules of nucleic acid no containing retrovirus particles are incorporated also. Nucleic acid molecule has the sequence that encodes protein which involves at least one epitope identical or similar with antigen epitope being the latter is a target for immune response. This nucleotide sequence is bound operatively with regulatory sequences. Invention describes also a pharmaceutical composition and set for method realization. EFFECT: broadened arsenal of agents against HIV infection. 48 cl, 1 tbl, 19 dwg, 59 ex
Administration of 1, 2 or 4 doses of NVX-508 at three dose levels; 0.05ml/kg. 0.1ml/kg and 0.17ml/kg in a 3 + 3 design.
NEW MATERIAL:A monoclonal antibody, produced by a hydridoma prepared by using cholangiocarcinoma-derived strain (HEK) as an immunological source and having the following characteristics. Ig class (subclass); IgG1. Recognition antigen type; Secretory type antigen. Reactivity with cancerous cells Capable of exhibiting positive reaction to at least gastric cencerous cell strain (KATO-III), (MKN-45) and (COLO-201). USE:A remedy and diagnostic agent or testing reagent for cancer. PREPARATION:For example, established cholangiocarcinoma cell (HEK cell) is incubated with an antihuman leukemic mouse antibody at room temperature and administered to immunize BALB/c strain mouse. Splenic cells are collected after the final immunization and then fused to myelomatous cells. Screening and cloning are carried out to afford a cloned hybridoma, which is then cultivated to provide the aimed monoclonal antibody.
The present invention relates to the application of make-up, and more particularly, to an implement for the efficient application of mascara to the eyelashes. Mascara is usually being applied after the bass make-up, powder, lipstick, etc. and is the final touch after all of the other make-up products have been applied. It is therefore an object of the present invention to provide an implement manufactured of any semi-hard material, such as compressed paper, plastic, processed paper and the like, with a least one concave edge meant to fit just above the eyelash to which the mascara is to be applied. By holding the implement substantially as described herein, only the eyelash is exposed to the mascara applicator, the skin of the eyelid remaining covered. Thus the accidental application of mascara to the skin, above or below the eye, is avoided.
Epigenetic alterations that lead to differential expression of microRNAs (miRNAs/miR) are known to regulate tumour cell states, epithelial-mesenchymal transition (EMT) and the progression to metastasis in breast cancer. This study explores the key contribution of miRNA-18a in mediating a hybrid E/M cell state that is pivotal to the malignant transformation and tumour progression in the aggressive ER-negative subtype of breast cancer. The expression status and associated effects of miR-18a were evaluated in patient-derived breast tumour samples in combination with gene expression data from public datasets, and further validated in in vitro and in vivo breast cancer model systems. The clinical relevance of the study findings was corroborated against human breast tumour specimens (n = 446 patients). The down-regulated expression of miR-18a observed in ER-negative tumours was found to drive the enrichment of hybrid epithelial/mesenchymal (E/M) cells with luminal attributes, enhanced traits of migration, stemness, drug-resistance and immunosuppression. Further analysis of the miR-18a targets highlighted possible hypoxia-inducible factor 1-alpha (HIF-1α)-mediated signalling in these tumours. This is a foremost report that validates the dual role of miR-18a in breast cancer that is subtype-specific based on hormone receptor expression. The study also features a novel association of low miR-18a levels and subsequent enrichment of hybrid E/M cells, increased migration and stemness in a subgroup of ER-negative tumours that may be attributed to HIF-1α mediated signalling. The results highlight the possibility of stratifying the ER-negative disease into clinically relevant groups by analysing miRNA signatures.
PURPOSE:To provide the curable compsn. of 4CP and/or alpha-TCP having practicable properties meeting applications as medical materials and dental materials. CONSTITUTION:This compsn. consists of the calcium phosphate powder subjected to surface reforming by a film treatment with a high-polymer compd., the powder essentially consisting of this powder and a hardener. The resulted compsn. has excellent bioaffinity and is excellent in terms of sufficient allowance time for operation and physical properties.
FIELD: chemical technology, pharmacy. SUBSTANCE: invention relates to the improved method for preparing the known anti-inflammatory substance mometasone furoate (I). (I) is prepared by direct esterification of 17-hydroxyl group of mometasone using 2-furoyl chloride in the presence of tertiary amine and inert solvent, preferably, dichloromethane without preliminary protection of free 11-hydroxyl group. For removal of formed enolfuroate additional treatment with hydrochloric acid is carried out. EFFECT: improved preparing method. 8 cl
Fludarabine \& Melphalan followed by autologous stem cell transplantation. Pembrolizumab will begin on Day +1.
Disrupted mitochondrial dynamics and mitophagy contribute to functional deterioration of skeletal muscle (SM) during aging, but the regulatory mechanisms are poorly understood. Our previous study demonstrated that the expression of thyroid hormone receptor α (TRα) decreased significantly in aged mice, suggesting that the alteration of thyroidal elements, especially the decreased TRα, might attenuate local THs action thus to cause the degeneration of SM with aging, while the underlying mechanism remains to be further explored. In this study, decreased expression of myogenic regulators Myf5, MyoD1, mitophagy markers Pink1, LC3II/I, p62, as well as mitochondrial dynamic factors Mfn1 and Opa1, accompanied by increased reactive oxygen species (ROS), showed concomitant changes with reduced TRα expression in aged mice. Further TRα loss- and gain-of-function studies in C2C12 revealed that silencing of TRα not only down-regulated the expression of above-mentioned myogenic regulators, mitophagy markers and mitochondrial dynamic factors, but also led to a significant decrease in mitochondrial activity and maximum respiratory capacity, as well as more mitochondrial ROS and damaged mitochondria. Notedly, overexpression of TRα could up-regulate the expression of those myogenic regulators, mitophagy markers and mitochondrial dynamic factors, meanwhile also led to an increase in mitochondrial activity and number. These results confirmed that TRα could concertedly regulate mitochondrial dynamics, autophagy, and activity, and myogenic regulators rhythmically altered with TRα expression. Summarily, these results suggested that the decline of TRα might cause the degeneration of SM with aging by regulating mitochondrial dynamics, mitophagy and myogenesis.
PROBLEM TO BE SOLVED: To obtain the subject agent slight in side effects on human body by including, as active ingredients, an activated vitamin D derivative and an anticancer agent. SOLUTION: This therapeutic agent for leukemia contains, as active ingredients, an activated vitamin D derivative and an anticancer agent. The activated vitamin D derivative is e.g. 1α-hydroxyvitamin D3 , 1α,25- dihydroxyvitamin D3 , 24F2 -1α,25-dihydroxyvitamin D3 ; while the anticancer agent is selected from chlorambucil, daunorubicin, hydroxyurea, Ara-C, camptothecin, and etoposide, etc. The activated vitamin D derivative and the anticancer agent can be formulated in the form of a mixture in a single agent; however, they may be prepared as separate agents in the form of a kit, and taken either simultaneously or in a time-shifted manner when to be used. This agent can inhibit the proliferation of leukemic cells in an extremely effective way and promote the differentiation induction of these cells.
In an X-ray imaging device (1) according to the present invention, an ID sticker printing unit (21) prints an ID sticker. The ID sticker is to be applied to a triage tag that is attached to a subject and the ID sticker bears a subject ID issued by an ID issuing unit (19). The subject ID identifies the imaged subject of a formed X-ray image. Thus, reference to the subject ID on the ID sticker applied to the triage tag enables identification of the imaged subject of the X-ray image. In addition, since the ID sticker bearing the subject ID is applied to the triage tag, the subject ID issued by the ID issuing unit (19) does not need to be hand-written onto the triage tag. Thus, a step of writing the subject ID can be omitted and a human error in doing so can be avoided. Therefore, the subject and the X-ray image acquired with respect to the subject can be efficiently and reliably associated.
BACKGROUND: Hepatocellular carcinoma (HCC) is a cancer with poor prognosis. Indonesia is a country with high prevalence of chronic hepatitis B infection. The performance of alpha fetoprotein (AFP) as a tumor marker in HCC surveillance is primarily influenced by the etiology of the underlying liver disease. We aimed to determine the best cut-off value of AFP biomarker examination for HCC surveillance in patients with chronic hepatitis B infection.
METHODS: The study collected medical record data of the Hepatobiliary Division of Dr. Cipto Mangunkusumo Hospital from the period of 2017 to 2023. A total of 506 subjects with chronic hepatitis B of all spectrums (hepatitis B without cirrhosis, liver cirrhosis, and early-stage HCC, BCLC 0 and A) were included by total sampling that was performed from 26 July 2023 to 31 August 2023. Determination of the AFP cut-off value was carried out using the receiver operating characteristics (ROC) method.  Results: For HCC surveillance caused by hepatitis B virus, ROC curve analysis resulted in an area under the curve (AUC) of 0.792 (95% CI, 0.719-0.866), and the cut-off value with the highest Youden index was 8.7 ng/ml, with 58% sensitivity, 94% specificity, positive predictive value (PPV)  56.14%, negative predictive value (NPV) 94.43%, positive likelihood ratio (LR+) 10.08, and negative likelihood ratio (LR-) 0.46.
CONCLUSION: The cut-off value of AFP in HCC surveillance on hepatitis B specific etiology is lower than the cut-off value of AFP in previous HCC surveillance which was not etiologically specific. The cut-off value of 8.7 ng/ml produces the best sensitivity and specificity for the cut-off value for HCC surveillance with hepatitis B etiology.
The invention discloses a traditional Chinese medicine composite for protecting livers and preventing liver injury and a preparation method and application thereof. The composite comprises the following bulk drugs in parts by weight: 20-30 parts of astraglus base, 10-15 parts of bighead atractylodes rhizome, 10-15 parts of tuckahoe, 10-15 parts of liquorice and 10-15 parts of Schisandra chinensis. The preparation method comprises the following steps of: adding water to the bulk drugs in percentage by weight and decocting, and concentrating until the concentration is equivalent to 0.55-0.75g.ml-1 which is the concentration of crude drugs. Proved by animal experiment pathological study, the spleen-tonifying and liver-protecting prescription of the invention does not have hepatotoxicity per se and has a certain function of preventing mice acute liver injury caused by CCl4. The prescription not only can relieve the liver injury of jasmine on normal mice but also can assist routine dosage of jasmine to prevent the mice acute liver injury caused by CCl4. The invention is safe and effective and has low price and is suitable for patients with chemical and medicament liver injury.
Participants will receive weekly phone call reminders to encourage their partners to attend the STI clinic for syphilis testing for up to 8 weeks after initial positive syphilis test for the participant. The participant ID number will be written on both the notification paper which partners should bring in with them and be given to the participant when the nurse calls.
With a global towering prevalence of index acute myocardial infarction (nonrecurrent MI, NR-MI), a high incidence of recurrent MI (R-MI) has emerged in recent decades. Despite the extensive occurrence, the promising predictors of R-MI have been elusive within the cohort of survivors. This study investigates and validates the involvement of distinct gene expressions in R-MI and NR-MI. Bioinformatics tools were used to identify DEGs from the GEO dataset, functional annotation, pathway enrichment analysis, and the PPI network analysis to find hub genes. The validation of proposed genes was conceded by qRT-PCR and Western Blot analysis in experimentally induced NR-MI and R-MI models on a temporal basis. The temporal findings based on RT-PCR consequences reveal a significant and constant upregulation of the UBE2N in the NR-MI model out of the proposed three DEGs (UBE2N, UBB, and TMEM189), while no expression was reported in the R-MI model. Additionally, the proteomics study proposed five DEGs (IL2RB, NKG7, GZMH, CXCR6, and GZMK) for the R-MI model since IL2RB was spotted for significant and persistent downregulation with different time points. Further, Western Blot analysis validated these target genes' expressions temporally. I/R-induced NR-MI and R-MI models were confirmed by the biochemical parameters (CKMB, LDH, cTnI, serum nitrite/nitrate concentration, and inflammatory cytokines) and histological assessments of myocardial tissue. These results underscore the importance of understanding genetic mechanisms underlying MI and highlight the potential of UBE2N and IL2RB as biomarkers for non-recurrent and recurrent MI, respectively.
A food additive compn., useful for retarding the aging process and protecting the lung tissue from atmospheric pollutants, comprises: (a) a sulphur-contg. amino-acid, (b) selenium, (c) an antioxidant consisting of vit. E or mixts. of vit. E and a synthetic antioxidant lipid, the amount of vit. E present being in excess of that reqd. to form an organo-Se synergistic complex, (d) a cell-membrane stabiliser. It is useable for both man and animals.
Prospective, multi-center, single arm study designed to evaluate the safety and performance of the Shockwave Coronary Rx Lithoplasty® System to treat calcified lesions in the coronary arteries for the purpose of enhancing the placement of stents and reducing the ultimate residual stenosis. Patients will be enrolled and consented in the study based on history and in some instances an angiogram obtained prior to the study. The study is designed to demonstrate that the Shockwave device can safely and effectively deliver localized shockwave energy for balloon dilatation of calcified, stenotic, coronary arteries. Subjects will be prepared for PCI per the institution's standard protocol. Medications will be administered per the treatment protocol. Femoral access will be obtained using a 6F access sheath, and guiding catheter placed at the ostia of the right or left coronary artery. Baseline angiography of the culprit lesion will be performed prior to placement of a 0.014" guide wire. Baseline and either IVUS or OCT will be performed to determine the Maximum Lumen Area (MLA), percent stenosis, and volumetric lesion assessment. Baseline angiography will be performed to determine lesion length, % stenosis and reference vessel diameter. The investigational device will be prepped per the IFU and positioned at the target lesion. The distal end of the balloon catheter will be connected to the patient cable. The balloon catheter will be inflated to 4 atm and the investigator will deliver 10 pulses for 20 seconds. The balloon will then be inflated to reference vessel diameter and then deflated to reestablish flow and complete one treatment cycle. The treatment cycle will then be repeated. Angiography and either IVUS or OCT will be repeated for the treated lesion.. A coronary stent will be deployed at the site of treatment. Angiography and either IVUS or OCT will be performed following stent placement. Patients will be followed through discharge and at 30 and 180 days. A subset of up to five (5) subjects will receive an angiographic assessment at the 180 day follow up visit, per the Sponsor's discretion.
This invention relates to biologically active copolymers and compounds which can safely be used to increase the size of the thymus in an animal or a human being, thus resupplying the population of T-lymphocytes. When injected into an animal or human being with an antigen, the biologically active copolymers produce immunosupression of the antigen. The biologically active copolymers are also useful as growth promoters in animals. The compounds with biologically active copolymers according to this invention are effective tumoricidal agents. The biologically active copolymer according to this invention is a formulation which offers safety and is non- toxic and can be effectively administered to animals or human beings. The biologically active copolymer can be mixed in oil and water emulsion and administered to an animal or human being by injection.
There is disclosed a molecular composition(s) of a novel tissue protective erythropoietin (EPO) binding receptor protein complex, termed NEPOR. Presence of NEPOR components on a tumor allows EPO to impinge on the survival of associated cells thereby enhancing tumor progression and negatively effecting patient survival. Presence of NEPOR represents a prognostic biomarker for poorer patient outcome. Thus, methods are provided for stratifying patients having a tumor as suitable (i.e. NEPOR not present) or non-suitable (i.e., NEPOR present) for EPO treatment, comprising: (a) isolating a tissue sample from an individual who is receiving or is a candidate for receiving erythropoietin, (b) determining the level of expression of the NEPOR gene(s) (mRNA) and/or the presence of the NEPOR gene product (protein) from the isolated tissue, and (c) correlating the presence of an NEPOR gene expression product or the presence of NEPOR protein to a physiological response to the treatment with erythropoietin. Furthermore, by disclosing the molecular compositions of NEPOR species, there are disclosed methods for rationally identifying/designing NEPOR modulating therapeutics. Methods also are provided for treating neurological insults such as stroke (via enhancement of NEPOR activity) and cancer (via down-regulation of cyto-protective signaling from NEPOR).
FIELD: medicine, allergology, dermatology. SUBSTANCE: invention relates to treatment of patients with atopic dermatitis. Method involves the topical use of glucocorticoid ointment containing heparin additionally being this ointment is applied on damaged foci. Steroid dose is decreased by 13-40 times. EFFECT: enhanced effectiveness of treatment, decreased complications of steroid therapy. 3 tbl, 1 ex